Patient-Reported Outcome Measures in Routine Hematology Cancer Care

被引:0
作者
Kirkpatrick, Suriya [1 ]
Campbell, Karen [2 ]
Harding, Samantha [1 ]
Rudd, Sarah [1 ]
机构
[1] North Bristol NHS Trust, Bristol, England
[2] Edinburgh Napier Univ, Edinburgh, Scotland
关键词
Hematology cancer; Patient needs; Patient-reported outcome measures; Tools; CLINICAL-PRACTICE; MULTIPLE-MYELOMA; IMPACT; GUIDANCE; HEALTH; TOOL;
D O I
10.1097/NCC.0000000000001417
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundHematological cancers have devastating effects on patients' physical, emotional, and psychosocial health. There is growing evidence to support the use of patient-reported outcome measures (PROMs) through validated tools. Although PROMs are widely adopted in oncology, uptake in hematology remains limited in routine clinical care.ObjectiveThis review seeks to explore the utility of PROMs in routine hematology clinical practice and to understand the extent and type of evidence in relation to benefits of PROMs to patients.MethodsThe review was conducted in accordance with the Joanna Briggs Institute methodology for scoping reviews and the Preferred Reporting Items for Systematic reviews and Meta-Analysis scoping review model for organizing information.ResultsTen thousand and seventy-one articles were identified, 110 full texts were reviewed, and 14 articles met the final inclusion criteria. More than 20 individual outcome measures were identified that fell into the following categories: accessibility and usability, self-efficacy, shared decision-making, and implementation.ConclusionsStudies focused primarily on the choice of PROM, acceptability and usability, motivation for use, patient and healthcare professionals' experience of using PROMs, the stated value of PROMs, and implementation advice. However, there are limited published studies supporting how PROMs can be adopted into routine care for people with hematological cancer.Implications for PracticeThere are various validated PROMs but limited research on how to meaningfully implement them to improve clinical and patient outcomes in the routine care of hematology patients.
引用
收藏
页数:8
相关论文
共 44 条
[1]  
Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI DOI 10.1080/1364557032000119616
[2]   Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial [J].
Basch, Ethan ;
Deal, Allison M. ;
Kris, Mark G. ;
Scher, Howard I. ;
Hudis, Clifford A. ;
Sabbatini, Paul ;
Rogak, Lauren ;
Bennett, Antonia V. ;
Dueck, Amylou C. ;
Atkinson, Thomas M. ;
Chou, Joanne F. ;
Dulko, Dorothy ;
Sit, Laura ;
Barz, Allison ;
Novotny, Paul ;
Fruscione, Michael ;
Sloan, Jeff A. ;
Schrag, Deborah .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :557-+
[3]   Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study [J].
Bennink, Christine ;
de Mul, Marleen ;
van der Klift, Marjolein ;
Broijl, Annemiek ;
Tick, Lidwine ;
de Jongh, Eva ;
Garvelink, Mirjam ;
Lobbezoo, Dorien ;
Sonneveld, Pieter ;
Hazelzet, Jan .
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2023, 16 (03) :255-264
[4]   Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study [J].
Biran, Noa ;
Kouyate, Robin Anthony ;
Yucel, Emre ;
McGovern, Gillian E. ;
Schoenthaler, Antoinette M. ;
Durling, Olivia G. ;
Unawane, Rashmi ;
Schutt, Andrew ;
Panjabi, Sumeet .
JMIR FORMATIVE RESEARCH, 2020, 4 (11)
[5]  
Blood Cancer UK, News and blogs
[6]   Holistic needs assessment in advanced, intensively treated multiple myeloma patients [J].
Boland, E. G. ;
Boland, J. W. ;
Ezaydi, Y. ;
Greenfield, D. M. ;
Ahmedzai, S. H. ;
Snowden, J. A. .
SUPPORTIVE CARE IN CANCER, 2014, 22 (10) :2615-2620
[7]   The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma [J].
Davies, Joanna M. ;
Osborne, Thomas R. ;
Edmonds, Polly M. ;
Schey, Steve A. ;
Devereux, Steve ;
Higginson, Irene J. ;
Ramsenthaler, Christina .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (05) :508-516
[8]   Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma [J].
Dimopoulos, M. A. ;
Chen, C. ;
Spencer, A. ;
Niesvizky, R. ;
Attal, M. ;
Stadtmauer, E. A. ;
Petrucci, M. T. ;
Yu, Z. ;
Olesnyckyj, M. ;
Zeldis, J. B. ;
Knight, R. D. ;
Weber, D. M. .
LEUKEMIA, 2009, 23 (11) :2147-2152
[9]   What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence [J].
Easpaig, Brona Nic Giolla ;
Tran, Yvonne ;
Bierbaum, Mia ;
Arnolda, Gaston ;
Delaney, Geoff P. ;
Liauw, Winston ;
Ward, Robyn L. ;
Olver, Ian ;
Currow, David ;
Girgis, Afaf ;
Durcinoska, Ivana ;
Braithwaite, Jeffrey .
BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)
[10]  
Galinsky J., 2019, Cancer Nurs Pract, V8, P29